SABCS 2024 - Complete program listing (26 programs)

Daily recaps and interviews from the SABCS 2024

DAY 4

On SABCS 2024's final day, Dr. Jean-Pierre Ayoub discusses three key abstracts, including NSABP B-59/GBG-96-GeparDouze on immunotherapy in TNBC and a subgroup analysis of TAILORx exploring chemotherapy variations. Valuable insights shared!

Dr. Nagi S. El Saghir, Director at NKBCI in Beirut, highlights six key abstracts from SABCS 2024. He shares insights on the rich multidisciplinary data presented this year, spanning innovations in breast cancer research and treatment.

Prof. Amelie Ramirez discusses the importance of advancing research in prevention and treatment adherence for underserved Hispanic populations. She emphasizes clinical trial access and tailored treatments to combat breast cancer, a leading cause of death in this community.

Dr. Antonio Wolff shares expert commentary on SABCS 2024 highlights, including the practice-changing PATINA study, DCIS data, the COMET study, and the FDA's discussion on the importance of ovarian toxicity monitoring during clinical trials.

Dr. Rita Sakr, Head of Surgery at Emirates Hospital Dubai, discusses breast cancer survivors’ perspectives on de-escalation treatments in the Arab world and emphasizes the importance of education and raising awareness on de-escalation protocols.

Dr. Aydah AlAwadhi from the UAE shares insights on obesity's impact on breast cancer prevention, risk reduction, and prognosis, with key takeaways from Dr. H. Pan's (EBCTCG) presentation. She emphasizes the critical need for education and strategies to combat obesity in breast cancer patients.

Barbara Segarra-Vazquez, patient advocate and 2x breast cancer survivor, highlights drug optimization at SABCS 2024, emphasizing initiatives like Project Optimus and the importance of flexible dosing to enhance patients’ quality of life.

Dr. Saima Hassan, Surgical Oncologist at the CHUM in Montreal and co-author of the B-59/GeparDouze study, emphasizes Quebec's role, contributing 17% of patients. She discusses the study's findings, its implications, and the need for further biomarker exploration.

Prof. Amelie Ramirez reflects on SABCS 2024, highlighting advances from prevention to survivorship, the vital role of patient advocates in guiding research, and how new discoveries are improving the lives of breast cancer survivors.

Prof. Rebecca Dent discusses defining TNBC and shares updates from the KEYNOTE-522 study on neoadjuvant pembrolizumab for high-risk, early-stage TNBC. A detailed review of the progress and insights shaping TNBC management today.

Dr. Joseph Gligorov discusses the pivotal PATINA trial results, emphasizing its significance as one of the most important data sets presented at SABCS 2024, with implications for advancing treatment in metastatic breast cancer.

Dr. Paolo Tarantino reviews two practice-changing trials presented at SABCS, EMBER-3 and PATINA. He discusses his own presentation on real-world data and innovative biomarkers for optimizing ADC use in breast oncology.

DAY 3

Day 3 of SABCS 2024 reviewed by Drs. Sideris, Ayoub, and guest Dr. Ipshita Prakash, covering results from EUROPA, COMET, INSEMA, and PATINA trials. Key themes: de-escalation in treatment and a patient-centered care approach.

On Day 3, Dr. Stephanie Wong discussed the exciting results of the INSEMA trial, the second study showing that sentinel lymph node biopsy can be successfully omitted. We're eagerly awaiting further details to see if this approach can be widely implemented in practice.

Dr. Jean-Pierre Ayoub shares insights on the DESTINY-Breast12 trial, highlighting the reassuring effects of T-DXd on quality of life and neurological function in HER2+ metastatic breast cancer patients, with or without brain metastases.

Dr. Jean-Pierre Ayoub discusses the evolving field of ADCs in Canada, comments on additional analysis from DESTINY-Breast06 by Dr. Aditya Bardia, and explores the expanding indications for trastuzumab deruxtecan (T-DXd).

Dr. Mitchell Elliott presents his spotlight poster on Day 3, evaluating the Pathlight Assay, a new ultra-sensitive ctDNA assay, in the early breast cancer setting. Discover the potential of this innovative diagnostic tool.

Dr. Xiaofu Zhu provides key takeaways from important abstracts at SABCS, including the EMBER-3 study, the exciting phase 2 SOLTI VALENTINE study, and highlights from several de-escalation studies.

Dr. Lisa Carey highlights the practice-changing PATINA trial, a mature study addressing the critical question of whether CDK4/6 inhibitors improve outcomes when added to antiestrogen and anti-HER2 therapies in first-line treatment of metastatic HR+/HER2+ breast cancer.

Dr. Kevin Kalinsky explores the impact of omitting axillary staging on adjuvant therapy in ER+ breast cancer. From SABCS' clinical controversy session, discover 4 key insights on systemic therapy implications.

DAY 2

Drs Lucas Sideris, Jean-Pierre Ayoub, and guest Cristiano Ferrario discuss Day 2 highlights including metastatic and early breast cancer updates, PADMA and EMBER-3 results, PRO B study insights, OlympiA follow-up, and what to expect on Day 3

Join Dr. Aditya Bardia as he explores the efficacy and safety of trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy in the latest DESTINY-Breast06 analysis.

Dr. Jane Meisel discusses key Day 2 updates from SABCS, including Dr. Matteo Lambertini's study on risk-reducing surgeries and survival in young BRCA carriers and the OlympiA Phase 3 10-year follow-up. These findings underscore advances and the importance of BRCA testing in early breast cancer.

Dr. Marie-France Jilderda discusses findings on the Adjusted Breast Cancer Index Model, exploring its role in identifying HR+ breast cancer patients at minimal 10-year distant recurrence risk and the key rationale behind this critical investigation.

DAY 1

Join Dr. Asselah and Dr. Sidéris as they review Day 1 of SABCS 2024, discussing late-breaking abstracts, key updates, and whether this year's findings could bring practice-changing advancements in breast cancer care.

Dr. Edith A. Perez, Professor Emeritus at Mayo Clinic, Chief Scientific Officer at oncoXchange, and an internationally recognized translational researcher and cancer specialist, previews SABCS 2024. She shares insights on the most anticipated abstracts and studies, highlighting exciting and potentially practice-changing results that could shape the future of breast cancer care.